Galapagos, Servier deal

Galapagos received a €3 million ($3.9 million) milestone payment from Servier under a 2010 deal to discover and develop small molecules against undisclosed targets for osteoarthritis (OA). The payment was triggered by the delivery of osteoarthritis molecules.

Under the deal, Galapagos is responsible for discovery and development of small molecules against undisclosed targets through Phase I testing, at which point Servier has an option to license the compounds and assume responsibility for further clinical development and commercialization. ...